Briefs

London, UK and Cambridge, MA, USA, August 30, 2005 - InforSense Ltd, the leader in integrative analytics platforms, today announced that the National Cancer Institute (NCI), the US Federal Government's principal agency for cancer research, has chosen InforSense technology for high-throughput genetic data analysis in cancer research. Investigators at the Core Genotyping Facility (CGF) of the NCI, Gaithersburg, MD, USA, will use InforSense�s workflow-based integrative analytics platform, InforSense KDE, for rapid application development for their own research and also plan to publish cutting-edge analysis methods via a web portal to the wider research community.

For further information on InforSense products and solutions, visit www.inforsense.com.